Mind Medicine (MindMed) Inc. (OTCMKTS:MMEDF – Get Free Report) shot up 0.1% during mid-day trading on Friday . The stock traded as high as $44.97 and last traded at $43.82. 1,417,292 shares changed hands during trading, a decline of 58% from the average session volume of 3,376,665 shares. The stock had previously closed at $43.77.
Mind Medicine (MindMed) Stock Performance
The business’s 50 day simple moving average is $43.58 and its 200 day simple moving average is $28.49.
About Mind Medicine (MindMed)
Mind Medicine (MindMed) is a clinical-stage biotechnology company focused on developing innovative therapies derived from psychedelic compounds to address mental health disorders and addiction. The company’s research pipeline includes programs based on LSD, psilocybin and 18-methoxycoronaridine (18-MC), targeting conditions such as anxiety disorders, attention-deficit/hyperactivity disorder (ADHD) and opioid dependence. MindMed seeks to build a portfolio of drug candidates that combine pharmacological efficacy with optimized dosing regimens and delivery methods.
Founded in 2019 and headquartered in New York City, MindMed operates research facilities in North America and Europe, collaborating with academic institutions and medical centers to advance its clinical trials.
Further Reading
- Five stocks we like better than Mind Medicine (MindMed)
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Mind Medicine (MindMed) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mind Medicine (MindMed) and related companies with MarketBeat.com's FREE daily email newsletter.
